Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
125M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
87.8M
-
Shares change
-
+8.58M
-
Total reported value, excl. options
-
$405M
-
Value change
-
+$42M
-
Number of buys
-
61
-
Number of sells
-
-53
-
Price
-
$4.62
Significant Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) as of Q2 2022
140 filings reported holding MRSN - Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.8M shares
of 125M outstanding shares and own 70.39% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (9.01M shares), BlackRock Inc. (8.88M shares), Bain Capital Life Sciences Investors, LLC (8.66M shares), Avoro Capital Advisors LLC (7.55M shares), VANGUARD GROUP INC (4.73M shares), MILLENNIUM MANAGEMENT LLC (4.38M shares), Sarissa Capital Management LP (4.3M shares), Rock Springs Capital Management LP (4.08M shares), Bellevue Group AG (3.9M shares), and Woodline Partners LP (3.16M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.